Pharmacogenetics and Genomics

Aims & Scope

​​​​Pharmacogenetics and Genomics is devoted to the rapid publication of research papers, brief review articles and short communications on genetic determinants in response to drugs and other chemicals in humans and animals.

The Journal brings together papers from the entire spectrum of biomedical research and science, including biochemistry, bioinformatics, clinical pharmacology, clinical pharmacy, epidemiology, genetics, genomics, molecular biology, pharmacology, pharmaceutical sciences, and toxicology.

Under a single cover, the Journal provides a forum for all aspects of the genetics and genomics of host response to exogenous chemicals: from the gene to the clinic.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.7
2024	1.70

SJR (SCImago Journal Rank)

Year	Value
2024	0.553

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	154

Journal Rank

Year	Value
2024	10535

Journal Citation Indicator

Year	Value
2024	167

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Doxorubicin pathways

  Citation: 1373

  Authors: Caroline F., Connie, Sharon, Tina, Howard, Teri E., Russ B.

• Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily

  Citation: 705

  Authors: Peter I., Karl, Brian, Chantal, Shin-ichi, Takashi, John O., Ida S., Daniel W.

• Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

  Citation: 561

  Authors: Shuen-Iu, Wen-Hung, Shiou-Hwa, Wen-Chieh, Yun-Ting, Woan-Ruoh, Shu-Ling, Meng-Tse, Gwo-Shing, Tak-Wah, Pa-Fan, Wei-Hsuan, Han-Yu, Wu-Hsiang, Chun-Yu, Yi-Hui, Yau-Li, Juei-Jueng, Yuan-Tsong

• A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

  Citation: 521

  Authors: Christine, Nicolas, Peggy, Neil, Laure, Sima, Luigi, Jan-Nico, Alexis, Claudia, Martin, Jean-Claude, Alain, Maja

• SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

  Citation: 429

  Authors: Marja K., Mikko, Pertti J., Mikko

• Metformin pathways

  Citation: 396

  Authors: Li, Srijib, Kathleen M., Russ B., Teri E.

• Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

  Citation: 391

  Authors: Danxin, Andrew D., Audrey C., Deanna L., Wolfgang

• Very important pharmacogene summary

  Citation: 375

  Authors: Laura M., Svetlana M., Leslie W., Jason M., Deanna L., Teri E., Russ B.

• Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

  Citation: 341

  Authors: Wichittra, Thawinee, Pei, Pao-Yu, Somsak, Usanee, Pachadaporn, Parinya, Suda, Charoen, Pornrith, Alisara, Wongwiwat

• Valproic acid pathway

  Citation: 332

  Authors: Yogita, Caroline F., Jatinder K., J. Steven, Wen, Angela K., Russ B., Teri E.

---